Astrazeneca Pharma India Limited · NSE:ASTRAZEN
Astrazeneca Pharma India — Shareholder Meeting (August 2019)
27 slides from Astrazeneca Pharma India's shareholder meeting presentation, Aug 7, 2019
Slide 1: 40th Annual General Meeting
40TH ANNUAL GENERAL MEETING 07th AUGUST 2019 Gagan Singh
Slide 2: Disclaimer
DISCLAIMER This presentation by AstraZeneca Pharma India Limited (the “Company”) is solely for general information purposes only and may not be taken away, distributed, reproduced, or passed on, directly or indirectly, to any other person or published in whole or in part, in any manner. This present
Slide 3: Overview, India Market Overview, Sustainability, Innovation, Great Place to Work
1 Overview 2 India Market Overview 3 Sustainability 4 Innovation 5 Great Place to Work
Slide 4: What we set out to do: Return to Growth
What we set out to do Strategic priorities 1 2 3 Achieve Scientific Return to Be a great place Leadership Growth to work 4
Slide 5: Continued Pipeline Progress
Continued Pipeline Progress Highlights from the late-stage development Pipeline News Oncology Imfinzi SCLC1 Lynparza ovarian cancer (1st line, BRCAm2) pancreatic cancer (BRCAm) Trastuzumab Deruxtecan breast cancer (3rd line, HER2+3) Calquence CLL4(relapsed/refractory) CLL (treatment‐naïve) BioPharma
Slide 6: Our Purpose
Our Purpose We push the boundaries of science to deliver life‐changing medicines As we enter the next phase in our journey, the fundamentals of our strategy and plans remain unchanged, with Product Sales growth driving improved profitability and the generation of increasing levels of cash. Pascal So
Slide 7: AZ Global registers strong sales growth
AZ Global registers strong sales growth… Launches in India are subject to market potential. Regulatory approval and commercial viability. 7 Source : FY 2018 Presentation, conference call and webcast for investors and analysts
Slide 8: Overview, India Market Overview, Sustainability, Innovation, Great Place to Work
1 Overview 2 India Market Overview 3 Sustainability 4 Innovation 5 Great Place to Work
Slide 9: Positive outlook for the industry fuelled by macro economic factors and domestic demand
Positive outlook for the industry fuelled by macro economic factors and strength of domestic demand Macro-environment1 Healthcare (HC) spend2,3 GDP growth rate projected as ~7.4% for 2019 and ~7.7% HC spend as % of GDP : 4.1% for 2020 Increase in Government HC spend from ~1.2% to Indian economy set
Slide 10: Late stage pipeline and key lifecycle medicines
Committed to impacting patient lives over next few years with upcoming launches and pipeline* ONCOLOGY CARDIOVASCULAR RENAL AND RESPIRATORY METABOLIC DISEASE Late stage pipeline and key lifecycle medicines Lokelma hyperkalemia Bevespi Qtern COPD diabetes Dapa HF diabetes Dapa CKD Diabetes and Non Di
Slide 11: AZ Growth vs Market
AZ Growth vs Market AZ’s active portfolio growing at 2X MAT IPM growth of 10.4%. IPM MNC LOCAL AZ Active + Partner AZ Active 30.0% 28.3% Implementat ion of GST 25.0% 20.0% 19.7% 15.0% 10.9% 10.0% 10.4% 8.6% 5.0% 0.0% Q2 MAT 17 Q3 MAT 17 Q4 MAT 17 Q1 MAT 18 Q2 MAT 18 Q3 MAT 18 Q4 MAT 18 Q1 MAT 19 Q2
Slide 12: AstraZeneca India: Fastest growing company amongst top-10 MNCs
AstraZeneca India: Fastest growing company amongst top-10 MNCs (MAT Jun’19) Rank Company Total revenue $m Val Market share (MNC Only) MAT MAT QTR GR% QTR 2’19 GR% GR% GR% Jun’19 Jun’19 2’19 1 ABBOTT 1186.6 11% 311.4 9% 32.2% 2.3% 32.4% 1.3% 2 GLAXOSMITHKLINE 554.2 10% 137.4 7% 15.0% 1.0% 14.3% ‐1.1%
Slide 13: Track record of successful launches in CV-Met TA
Track record of successful launches in CV-Met TA TICAGRELOR becomes #1 OAP replacing CLOPI in Value MS 2018 Ranks #142 of Top 200 brands in IMS Improves 21 ranks from MAT Mar ‘18 Source‐ IQVIA MAT Dec ‘18 13 Source: IQVIA database MAT March 2018
Slide 14: AZ Oncology ranked No. 6 among MNCs in India
AZ Oncology ranked No. 6 among MNCs in India Launch of new innovative portfolio driving growth 43% Ranked no. 6 * %age Contribution 12% among MNCs; 100% 88% 57% up 4 ranks in 1 yr 2016 2017 2018 Core Onco New Onco 14 * AZ Oncology (MAT Dec’18)
Slide 15: Overview, India Market Overview, Sustainability, Innovation, Great Place to Work
1 Overview 2 India Market Overview 3 Sustainability 4 Innovation 5 Great Place to Work
Slide 16: Sustainability Journey
Sustainability Journey Spotlight on Access to Healthcare Our commitment towards issue of NCDs Name 19 August 2019
Slide 17: What we're doing: access to healthcare
What we’re doing… doing…. 60% Non‐communicable diseases account for 60% of deaths In India . 40 year celebrations with Community Our strategy for Access to We’re making Healthcare focuses onour threescience areas: Early Cancer Screening for Women accessible by designing and • Making our medicines av
Slide 18: Educating community on risk behaviours associated with NCDs
Educating National Community Service Week in partnership community on with Plan India to celebrate 40 years in India risk behaviours associated with The objective was to raise awareness and understanding about the risk behaviours associated with common NCDs among young people from NCDs marginalised
Slide 19: Ganga Godavari Early Cancer Screening Programme for Women
Ganga Godavari Early Cancer Screening Programme for Women The programme was launched in partnership with Indian Cancer Society & CAF India on World Cancer Day (4th Feb 2019) with aim to: Conduct specialized check‐up of cancer for females in defined population for oral, cervical and breast cancer i
Slide 20: Collaborations with state governments to improve access and quality of care
Collaborations with state governments to improve access and quality of care 20 Kerala Health Minister inaugurating the 2019Name 19 August Centre of Excellence in Kerala
Slide 21: Overview, India Market Overview, Sustainability, Innovation, Great Place to Work
1 Overview 2 India Market Overview 3 Sustainability 4 Innovation 5 Great Place to Work
Slide 22: Use of emerging technologies across patient journey
Use of emerging technologies across patient journey Prevention to Early Diagnosis Diagnosis & Treatment Post-treatment 诊前 诊中 诊后 National Smart Validation of Electronic Follow-up Tracking helpline diagnostics diagnosis records treatment recovery Self-assessment Access to specialists Wearables Virtual
Slide 23: Unnati Healthcare 2.0 Innovation Challenge
Unnati Healthcare 2.0 Innovation Challenge 90+ applications received Unnati Winner: 50+ unique screened applications 19 from Bangalore, 9 Delhi NCR, 5 ten3T-Smart Patch real-time monitoring device which Hyderabad, 4 Chennai, 3 Mumbai, 3 Pune, measures 6 Lead ECG, pulse, respiration, temperatur
Slide 24: Overview, India Market Overview, Sustainability, Innovation, Great Place to Work
1 Overview 2 India Market Overview 3 Sustainability 4 Innovation 5 Great Place to Work
Slide 25: Our Great Place to Work Success Levers
Our Great Place to Work Success Levers
Slide 26: Impact of our GPTW Strategy
Impact of our GPTW Strategy Ahead of IPM in Gender-diversity AZ India Great Place to work certified by GPTW Institute ASIA AREA ASIA AREA Country Cultural of the year Award Transformation Award
Slide 27: Confidentiality Notice
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or dis
AstraZeneca Pharma India — Shareholder Meeting (August 2019) on 6ix